Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Introduction: antipsychotic induced agranulocytosis
3. Adverse drug reactions (IDR)
4. Classification of adverse drug reaction
5. Diagnosing an adverse drug reaction
6. Agranulocytosis (AG)
7. High incidence drugs
8. Drug induced agranulocytosis in Spain
9. Incidence rates of agranulocytosis
10. Hypothesized etiological mechanisms
11. Characteristics of IDR
12. Errors of metabolism?
13. Clozapine-AG
14. History
15. Treatment options
16. Pathomechanisms/genetic research data
17. HLA alleles
18. HLA class I in clozapine-AG
19. HLA class II in clozapine-AG
20. Further HLA-data
21. HLA Cw7 in non-Jewish Caucasians
22. Association with HLA-alleles
23. Other HLA related mechanisms
24. FC-gamma receptors
25. FC-gamma related pathways?
26. Non immunologic pathways
27. Is NQO2 gene a candidate?
28. Impact of MPO and NADPH-oxidase
29. Non immunologic candidates
30. No impact of MPO/NADPH-oxidase
31. Topics of the future
32. Olanzapin-AG
33. History
34. Hematological toxicity?
35. Treatment options
36. Pathomechanisms/genetic research data
37. Genetic predisposition?
38. Feasibility of genetic testing
39. Needs for genetic tests?
40. Problems of predictive genetic tests?

Topics Covered

• Agranulocytosis
• Adverse drug reactions
• Etiological mechanisms
• Idiosyncratic drug reactions
• Genetic and immunologic background
• Antipsychotic induced agranulocytosis
• Clozapine
• Olanzapine
• Future strategies of research

Links

Series:

• Psychopharmacogenetics

Categories:

• Genetics & Epigenetics
• Immunology
• Neuroscience
• Pharmaceutical Sciences

Therapeutic Areas:

• Immunology & Inflammation
• Neurology

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on February 25, 2021

Financial Disclosures

• Dr. Michael Dettling has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.